




Searching News Database: BiovaxID
HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
HSMN NewsFeed - 21 Dec 2006
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
HSMN NewsFeed - 8 May 2006
Accentia Biopharmaceuticals Receives FDA Approval for Three Unique Dosage Combination Pain Product ANDAs
Accentia Biopharmaceuticals Receives FDA Approval for Three Unique Dosage Combination Pain Product ANDAs
HSMN NewsFeed - 12 Apr 2006
FDA Grants Accentia Biopharmaceuticals Fast Track Status for SinuNase(TM)
FDA Grants Accentia Biopharmaceuticals Fast Track Status for SinuNase(TM)
Additional items found! 1

Members Archive contains
1 additional stories matching:
BiovaxID
(Password required)
BiovaxID
(Password required)